TNF and rheumatoid arthritis: The primary objective of this study was to evaluate the safety of tofacitinib at two dosages (5 mg twice daily and 10 mg twice daily) compared with biologics anti-TNFα (etanercept or adalimumab) in subjects with rheumatoid arthritis (RA) with inadequate response to methotrexate, aged 50 years or older, and with at least one additional cardiovascular risk factor.